|
|
 |
Gastrointestinal agent
|
 |
Proton pump inhibitor
|
 |
Short-term treatment and maintenance of healing of erosive esophagitis, symptomatic GERD, pathological hypersecretory conditions
|
 |
Adults: Swallow whole. Treatment of EE: 40 mg once daily for up to 8 weeks; may repeat for 8 more weeks if symptoms remain. Maintenance of EE healing : 40 mg once daily. Pathological hypersecretory conditions: initially 40 mg twice daily; max 240 mg/day.
|
 |
CATEGORY B
|
 |
Bloating and gas, diarrhea, headache, rash, hyperglycemia(increased thirsty, frequent urination), diziness, itching
|
Pregnancy Risk Categories defined:
A: Studies in pregnant women failed to show a risk to the fetus in the first
trimester - with no evidence of risk in the later trimesters.
B: Animals studies indicate no adverse effect to the fetus, but there are no adequate,
clinical studies in pregnant women.
C: Animal studies have shown an adverse effect on the fetus, but there are no adequate,
clinical studies in humans. Despite potential risks, the drug may be useful in pregnant
women.
D: There is evidence of risk to the human fetus, but the potential benefits of use in
pregnant women may be acceptable, despite potential risks.
X: Studies in animals or humans show fetal abnormalities, or adverse reaction reports
indicate evidence of fetal risk. Warning: the risks involved clearly outweigh any
potential benefit from using the drug in pregnant women, regardless of trimester.
NR: Not rated (i.e., no information available at this time as to the potential
risks or benefits).
|
| | |
If you want your friend to read or know about this article, Click here
 |
|
|
